Newamsterdam Pharma Stock Investor Sentiment

NAMSW Stock   12.25  0.43  3.39%   
Slightly above 62% of NewAmsterdam Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are alarmed. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
  

NewAmsterdam Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Head to Head Contrast NewAmsterdam Pharma Pyxis Oncology - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
NewAmsterdam Pharma Pyxis Oncology Head to Head Contrast - Defense World
Google News at Macroaxis
over six months ago at benzinga.com         
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
benzinga news
over six months ago at news.google.com         
NewAmsterdam Pharma Director Acquires 181223.50 in Stock - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Johannes Jacob Piete Kastelein Sells 190476 Shares of NewAmsterdam Pharma Stock - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Johannes Jacob Piete Kastelein Sells 190,476 Shares of NewAmsterdam Pharma Stock - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
NewAmsterdam Pharma Sees Unusually-High Trading Volume - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Discretionary transaction by Louise Kooij of 213073 shares of NewAmsterdam Pharma subject to Rule 16...
Macroaxis News
over six months ago at news.google.com         
NewAmsterdam Pharma Shares Gap Up to 22.45 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
NewAmsterdam Pharma Shares Gap Up to 22.45 - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
Analysts Set NewAmsterdam Pharma Price Target at 30.00 - Defense World
Google News at Macroaxis
over a year ago at news.google.com         
Brokerages Set NewAmsterdam Pharma PT at 30.00 - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
NewAmsterdam Pharma Shares Down 3.1 percent - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
NewAmsterdam Pharma Full Year 2023 Earnings Revenues Miss Expectations - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
NewAmsterdam Pharma Company N.V. Just Reported Full-Year Earnings And Analysts Are Lifting Their Est...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about NewAmsterdam Pharma that are available to investors today. That information is available publicly through NewAmsterdam media outlets and privately through word of mouth or via NewAmsterdam internal channels. However, regardless of the origin, that massive amount of NewAmsterdam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewAmsterdam Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewAmsterdam Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewAmsterdam Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewAmsterdam Pharma alpha.

NewAmsterdam Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
NewAmsterdam Pharma Trading Up 4.7 percent - Heres What Happened - MarketBeat
12/17/2024
2
Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3
12/27/2024
3
Obicetrapibs data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.com
12/30/2024
4
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
01/10/2025
5
NewAmsterdam Pharma to Present at Guggenheims SMID Cap Biotech Conference
01/29/2025
6
NewAmsterdam Pharma Reaches 80-Plus Relative Strength Rating Benchmark - MSN
02/04/2025
7
Where are the Opportunities in - Stock Traders Daily
02/07/2025
8
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
02/25/2025
9
NewAmsterdam Pharma Company N.V. Yearly Results Heres What Analysts Are Forecasting For This Year - Yahoo Finance
02/28/2025
10
Stocks Showing Market Leadership NewAmsterdam Pharma Earns 92 RS Rating - Investors Business Daily
03/06/2025

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.